Allogene Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
TPG Funds have sold all their shares in Allogene Therapeutics, Inc. on September 28, 2026, marking the end of their significant beneficial ownership.
NASDAQ
Pfizer Inc. reported a decrease in its beneficial ownership of Allogene Therapeutics, Inc. common stock to 9.0%, solely due to an increase in Allogene's outstanding shares.